Mohit Bansal, an analyst from Wells Fargo, maintained the Hold rating on Biogen (BIIB – Research Report). The associated price target ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

The facility at a business park in Raheen, Limerick, was first announced in 2022 and this is the second time that Lilly has ...

For lecanemab, scientists at AAIC highlighted the promise of the fluid tau marker MTBR-243 to track tangle load, and they ...

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I'm Not Talking About Zepbound) ...

Alzheimer disease research is yielding breakthroughs with blood tests and brain scans that can enhance early diagnosis, while ...

As quantitative data replaced qualitative descriptions in the ads, and as information about severe adverse effects was ...

One of Eli Lilly and Company (NYSE:LLY)’s most significant advancements is donanemab, an experimental drug for Alzheimer’s ...

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

An experimental cancer drug that helps the brain turn glucose into energy was able to reverse memory loss in a mouse model of ...